Boost to Atmanirbhar Bharat: Adani Defence to Manufacture AK-203 Ammunition

Adani Defence & Aerospace has signed a five-year agreement with Indo-Russian Rifles Private Limited (IRRPL) to supply indigenously manufactured 7.62×39 mm ammunition for AK-203 assault rifles, marking a major boost to India’s Atmanirbhar Bharat defence initiative. The pact integrates rifle production and ammunition supply under one domestic framework, strengthening India’s self-reliance in small arms.

Key Highlights of the Agreement

• Parties involved: Adani Defence & Aerospace and Indo-Russian Rifles Private Limited (IRRPL)
• Duration: Five years
• Scope: Supply of 7.62×39 mm ammunition for AK-203 rifles
• Facility: Adani’s Kanpur plant will manufacture the ammunition
• Integration: Links IRRPL’s rifle production at Korwa, Amethi, with Adani’s ammunition supply

Background on the AK-203 Programme

• Origin: AK-203 is part of the Kalashnikov family, combining Russian design with Indian manufacturing
• Contract: In December 2021, India’s Ministry of Defence signed a contract for 6,01,427 rifles
• Production: IRRPL has delivered around 70,000 rifles from its Korwa factory
• Indigenisation milestone: The first 100% Indian-made AK-203 rifle, named “Sher”, was successfully test-fired

Strategic Significance

• Self-reliance: Reduces dependence on imported ammunition
• Economic impact: Supports India’s ₹5,124 crore rifle localisation programme
• Defence ecosystem: Strengthens private-sector participation
• Operational readiness: Guarantees steady ammunition availability

Challenges & Considerations

• Undisclosed contract value: Financial details remain confidential
• Execution risks: Timely delivery and quality assurance are critical
• Geopolitical sensitivity: Must navigate Indo-Russian defence dynamics

Quick Comparison: Rifle vs Ammunition Roles

AK-203 Rifle	Ammunition Supply
Manufactured by IRRPL at Korwa, Amethi	Manufactured by Adani Defence at Kanpur
Contract for 6,01,427 rifles	Five-year supply pact (volumes undisclosed)
Based on Kalashnikov design	7.62×39 mm calibre rounds
Delivered ~70,000 rifles so far	Ensures continuity of supply for contract period

Sophos Unveils Exploit Path Verification to Prioritize Real‑World Vulnerabilities with OpenAI Cyber Models

Sophos, a global cybersecurity leader, today announced Exploit Path Verification (EPV), a new capability that will be built into Sophos Managed Risk to help security teams better prioritize and manage exploitable vulnerabilities in their environment. The capability will be built with OpenAI's GPT cyber models through the Daybreak Defense Network, to return verified, evidence-backed verdicts that give defenders the clarity they need to fix the exposures that matter first. Availability will be announced at a later date.

Security teams face a widening gap between the vulnerabilities they can find and the ones they can fix. Scanners surface thousands of exposures and severity scores and rank them, but a severity score cannot tell whether a critical flaw sits behind a control that blocks it, or whether two low-severity findings chain into the path that leads to a breach. As a result, security teams often patch by generic score, rather than by whether an attacker could reach and use a flaw in their specific environment.

Sophos is designing EPV to close that gap. It is being built to reason over asset and patch state, endpoint protection policy, network reachability, identity and privilege facts, and known exploit availability, and returns a clear evidence-backed exploitability verdict:

• Confirmed Exploitable
• Blocked by a Control
• Not Reachable
• Insufficient Evidence

EPV will also be designed to identify chained paths where multiple lower-severity findings combine into one exploitable route, assess whether a control blocks a technique class or only a common public proof of concept, and draft remediation text ready for a ticket.

The capability will be advisory and additive by design. Every verdict is labeled as AI-generated with its evidence visible, and Sophos analysts review the results.

“One of the most common challenges we hear from security teams today is the volume of findings they need to sift through, and the lack of clarity of which findings matter most, or in other words, put them at greatest risk,” said John Peterson, chief technology officer, Sophos. “Exploit Path Verification is being built to make it clear what in their environment is reachable by an attacker, with the evidence to prove it, so they fix what counts first.”

EPV extends Sophos' work with OpenAI. Through the OpenAI Daybreak Defense Network (formerly OpenAI Daybreak Cyber Partner Program), which Sophos joined in June 2026, the company brought frontier cyber models into MDR investigation, advisory assessments, and workflows that help customers discover, validate, and remediate exposure. EPV will build on that work inside a product customers already run. OpenAI's GPT cyber models provide frontier reasoning to help assess exploitability. Sophos supplies the environment-specific evidence and product controls, and its analysts review the results delivered to customers.

“Our goal through the OpenAI Daybreak Defense Network is to give defenders the advantage of frontier AI, safely,” said McCall McIntyre, Head of Global Cyber Partnerships, OpenAI. “Sophos has been a thoughtful partner since joining the program, and Exploit Path Verification is a clear example of frontier reasoning applied to a real defensive problem, with the guardrails that responsible deployment demands.”

Sophos defends more than 625,000 organizations worldwide, including 40,000 managed detection and response (MDR) customers across enterprise, mid-market, and commercial segments, delivered through one of the industry's largest partner ecosystems. That reach is central to EPV's purpose. Verified exploitability should not be a capability reserved for the largest security teams with the deepest budgets.

EPV is in development for enterprise and mid-market business customers of Sophos Managed Risk. Sophos will announce availability, including early access and general availability timing, at a later date.

For more on Sophos Managed Risk, please visit sophos.com/services/managed-risk.

UPES Runway Invests ₹25 Lakh in Reagvis Labs to Advance AI‑Powered Digital Trust

Dr. Sachin Chaudhary, Co-founder, Reagvis Labs

UPES Runway, the startup incubator at UPES, announced an investment of ₹25 lakh through equity participation in Reagvis Labs, a deep-tech startup developing indigenous artificial intelligence solutions for digital trust, including deepfake detection, document forgery detection, digital identity verification and digital content authentication. The investment is part of UPES Runway’s initiative to identify and support promising AI-native and AI-driven ventures through capital, mentorship and access to the wider startup and investor ecosystem.

Founded in 2025 by Dr. Sachin Chaudhary and Dr. Praful Hambarde, Reagvis Labs grew out of an academic collaboration between the two researchers during their PhD journey. Working in artificial intelligence and computer vision, the founders witnessed the emerging challenges around the misuse of generative AI to create deepfakes, forged documents, synthetic identities and misleading digital content. Reagvis Labs was created to address challenges such as deepfakes, forged documents and synthetic identities, with capabilities spanning media manipulation detection, identity and content verification, and KYC across image, video and audio, by building AI-led technologies that strengthen trust in the digital ecosystem.

Rahul Nainwal, CEO, Runway Incubator and Dean, School of Business, UPES, said, “The next phase of AI innovation will not only be about what artificial intelligence can create, but also about whether we can trust what it creates. Reagvis Labs is working on a problem that will become increasingly important as synthetic content becomes more sophisticated and widespread. Through The Pitch, our objective is to identify such AI-led ventures with strong technology depth and meaningful real-world applications and give founders the capital and ecosystem support they need to build and scale.”

Dr. Sachin Chaudhary, Co-founder, Reagvis Labs, said, “Reagvis began with our belief that trust must become a fundamental layer of the AI-powered digital world. As generative technologies grow more powerful, the ability to distinguish authentic content from manipulated or synthetic content will become increasingly important for businesses, governments and individuals. The investment and support from UPES Runway will help us strengthen our technology, accelerate development and take our digital-trust solutions to a wider set of real-world applications.”

Through The Pitch 3.0, UPES Runway plans to support 10 innovators this year, with an investment of around ₹25 lakh per startup, and the potential for higher investment in exceptional AI-led ventures, subject to evaluation and approval. Pitch 3.0 recently concluded its Delhi leg, which attracted more than 20 applications and brought seven shortlisted startups before investors, mentors and UPES leaders. The ventures represented a wide range of sectors, including AI image recognition, fintech, edtech, disaster management, fleet technology, quantum computing and deep tech, reflecting the breadth of AI-led innovation emerging from India’s startup ecosystem. Startups - Arthik AI, StoreLink and Memintel were shortlisted in the Delhi round. The next leg of The Pitch is being planned in Bengaluru, as UPES Runway continues to identify and invest in niche AI businesses across different markets.

Through the Runway Incubator, UPES is also advancing its larger vision as an AI-first university, connecting academic and technological capabilities with entrepreneurship, funding and market opportunities. The initiative seeks to enable founders to take AI-led solutions beyond the laboratory or prototype stage and build ventures capable of addressing emerging industry and societal challenges.

Launched in 2021, Runway has grown into a platform for entrepreneurial development at UPES. In about five years, more than 200 startups have been incubated through Runway in association with DST-TIBI, MeitY, Shell E4, MaXcel Accelerator and Global University Systems.

For more information, please visit: runwayincubator.com

About UPES:

Established through the UPES Act, 2003, of the State Legislature of Uttarakhand, UPES is a top-ranked, UGC-recognised, private university. As per the National Institutional Ranking Framework (NIRF) 2025, the Ministry of Education, Government of India, UPES has been ranked 45 among universities, with a rank of 18 in Law, 36 in Management, and a rank of 43 in Engineering. As per the Times Higher Education (THE) World University Rankings 2026, UPES now stands in the 501-600 band globally and 5th in India, improving from 7th in 2025. Notably, in Research Quality, UPES jumped 57 positions in just one year to be ranked 299 globally. In addition to this, the university has been ranked the No.1 private university in academic reputation in India by the QS World University Rankings 2026. It is among the top 2% of universities in the world.

UPES has received 5 stars on Employability (placements) by the globally acclaimed QS Rating. 50+ faculty members from UPES feature among the world’s top 2% researchers as per the Stanford University list.

UPES offers graduate and postgraduate programs through its seven schools: School of Advanced Engineering, School of Computer Science, School of Design, School of Law, School of Business, School of Health Sciences & Technology, and School of Liberal Studies and Humanities. The UPES family includes 20000+ students, 1,500+ faculty and staff members, and a thriving community of 40000+ alumni that work across sectors in marquee brands like EY, KPMG, Bain and Co., McKinsey & Company, Capgemini, Google, Microsoft, Oracle, Nestle, ITC, Adani Power, ONGC, GMR, TCS, Wipro, Infosys, Amazon, Flipkart, Accenture, Deloitte and more.

Pixxel’s $100M Boost Fuels Hyperspectral Satellite Revolution

Image ~ Pixxel.com

Pixxel, the Google-backed Indian space-tech startup, has raised $100 million in a Series C round led by Temasek and Seraphim, marking India’s largest-ever private space-tech funding. This brings Pixxel’s total capital raised to $195 million and values the company between $400–500 million.

The $100M raise stands as India’s largest-ever space-tech funding round, underscoring Pixxel’s transition into its next growth phase as it expands across the entire space-tech value chain.

The fundraise arrives amid strong tailwinds for Pixxel. In just two years, the company has deployed six Firefly satellites to build the world’s highest-resolution commercial hyperspectral constellation, launched its Aurora Earth intelligence platform, and secured contracts with NASA and the NRO. It has also triumphed in multiple iDEX challenges from India’s Ministry of Defence, unveiled an orbital data-centre demonstration satellite, and been chosen to spearhead India’s first public-private Earth observation constellation of 12 satellites under IN-SPACe.

Key Funding Details

• Round size: $100 million (Series C)
• Lead investors: Temasek (Singapore) and Seraphim (UK)
• Other participants: Radical Ventures, growX Ventures, 360 ONE Asset, IMM Investment
• Total funding to date: $195 million
• Valuation: Estimated between $400–500 million

Strategic Expansion Plans

• Satellite Fleet Growth: Expansion of the Firefly hyperspectral constellation, upcoming Honeybee satellites, and sub-metre resolution satellites.
• Aurora Platform: Scaling its Earth intelligence software, which integrates satellite data with AI for actionable insights.
• Planetary Infrastructure Vision: Combining sensors, satellites, and AI to create a “health monitor for the planet.”

Why This Matters

• Largest space-tech fundraise in India: Positions Pixxel as the most well-funded Indian space startup, surpassing peers like Skyroot Aerospace.
• Global relevance: Hyperspectral imaging provides data beyond conventional satellite imagery, useful for climate monitoring, agriculture, defence, and resource management.
• Sovereign capability: Nations can leverage Pixxel’s systems for independent space missions and intelligence.

Comparison with Peers

Pixxel	Skyroot Aerospace
$195M total funding	$160M total funding
Focus: Hyperspectral satellites + AI Earth intelligence	Focus: Launch vehicles (rockets)
Valuation: $400–500M	Valuation: $1.1B (unicorn)
Backers: Temasek, Seraphim, Google	Backers: GIC, Lenskart’s Peyush Bansal

Challenges Ahead 

• Capital intensity: Satellite manufacturing and launches require sustained funding.
• Global competition: Rivals like Planet Labs and Satellogic already dominate hyperspectral imaging.
• Regulatory hurdles: India’s evolving private space policy could affect timelines and sovereign contracts.
• Execution risk: Scaling Aurora software and satellite fleets simultaneously is complex.

How Hospital Cost Estimates Can Guide Your Medical Insurance Coverage

Hospital cost estimates can help you judge whether your medical insurance coverage is likely to match the expenses you may incur during hospitalisation. By looking at treatment, room, procedure and related hospital charges, you can make a more informed decision about the level of cover you may need.

For people in India, this information is useful because treatment costs can vary by city, hospital category and type of care. A realistic estimate gives you a starting point for reviewing your sum insured and policy limits.
A hospital estimate gives an approximate view of what an admission or treatment may cost. It is not a final bill, but it can show the scale of hospitalisation before treatment starts.

The estimate may include:

• Room charges
• Doctor fees
• Procedure or surgery charges
• Diagnostic costs
• Medicines and consumables
• Nursing charges

Looking at these components helps you understand whether your insurance limit appears proportionate to hospital expenses.

How Estimates Help You Review the Sum Insured

The sum insured is the maximum amount available under the policy, subject to its terms. Hospital cost estimates can help you assess whether that limit matches the types of expenses you may incur.

If expected hospital charges are close to the available cover, there may be limited room for related costs during the policy period. This is why people reviewing their health care coverage can benefit from comparing the policy limit with realistic hospital cost information rather than considering the sum insured in isolation.

Why Room Charges Need Attention

Room charges can form a meaningful part of the hospital bill, particularly when the admission lasts several days. Some policies may also link room eligibility to other payable expenses, depending on the wording.

A cost estimate can help you check:

• The room category being considered
• Daily room charges
• Whether the policy has a room-rent condition
• Whether related charges are linked to room eligibility
• The likely effect of choosing a different room category

This comparison can help prevent a mismatch between the selected hospital room and the amount the policy may recognise.

How Procedure Costs Affect Coverage Needs

Hospital procedures can differ in complexity, equipment requirements and length of stay. Their expected cost can therefore be useful when judging whether the existing insurance limit is adequate.

A procedure estimate may show:

• Operation theatre charges
• Surgeon and anaesthetist fees
• Medical equipment costs
• Implant or device charges, where relevant
• Monitoring and recovery expenses

Reviewing these items alongside the policy can help you see whether any sub-limits, exclusions or specific conditions could affect the amount payable.

Why City and Hospital Types Can Change Estimates

Hospital charges are not uniform across India. Costs may differ between metropolitan cities, smaller cities, private hospitals, speciality centres and other facilities.

This matters because a sum insured that appears comfortable in one location may feel less adequate in a higher-cost setting. If you expect treatment in a particular city or hospital network, local cost estimates can provide more relevant information than broad assumptions.

The purpose is not to predict the final bill exactly but to understand the likely cost environment before deciding whether the available cover seems sufficient.

How to Compare Estimates with Policy Limits

Once you have a hospital estimate, compare it with the policy terms rather than only the headline sum insured. The amount payable can depend on conditions within the policy.

Check whether the estimate includes expenses affected by:

• Room-rent limits
• Procedure-specific sub-limits
• Co-payment clauses
• Deductibles
• Non-medical expenses
• Waiting periods
• Exclusions

This comparison helps reveal where the policy may cover the estimated expense fully, partly or not at all, subject to claim assessment.

Why One Estimate May Not Be Enough

A single hospital estimate may not represent every possible treatment situation. Costs can vary depending on the diagnosis, duration of admission, medical complications, hospital choice and treatment approach.

It can therefore be useful to review more than one cost range when assessing coverage. The aim is to understand whether the policy has enough room to absorb variation rather than matching one estimate exactly.

This approach gives a more realistic view of how the insurance limit may perform when hospital expenses differ from the initial estimate.

Conclusion

Hospital cost estimates can make medical insurance coverage easier to assess because they connect the policy limit with realistic treatment expenses. They help you review room charges, procedure costs, hospital location, sub-limits and other conditions that can affect the amount available during a claim.

Rather than choosing cover only by looking at a headline sum insured, comparing it with likely hospital costs gives you a clearer basis for judging adequacy. The final decision should still reflect the policy wording, because actual claim payments depend on the terms, exclusions and conditions that apply.